Reducing small intestinal permeability attenuates colitis in the IL10 gene-deficient mouse

Arrieta, M. C.; Madsen, K.; Doyle, J.; Meddings, J.
January 2009
Gut;Jan2009, Vol. 58 Issue 1, p41
Academic Journal
Background: Defects in the small intestinal epithelial barrier have been associated with inflammatory bowel disease but their role in the causation of disease is still a matter of debate. In some models of disease increased permeability appears to be a very early event. The interleukin 10 (IL10) gene-deficient mouse spontaneously develops colitis after 12 weeks of age. These mice have been shown to have increased small intestinal permeability that appears early in life. Furthermore, the development of colitis is dependent upon luminal agents, as animals do not develop disease if raised under germ- free conditions. Aims: To determine if the elevated small bowel permeability can be prevented, and if by doing so colonic disease is prevented or attenuated. Methods: IL10 gene-deficient (IL10-/-( mice) were treated with AT-1001 (a zonulin peptide inhibitor), a small peptide previously demonstrated to reduce small intestinal permeability. Small intestinal permeability was measured, in vivo, weekly from 4 to 17 weeks of age. Colonic disease was assessed at 8 weeks in Ussing chambers, and at 17 weeks of age inflammatory cytokines and myeloperoxidase were measured in the colon. Colonic permeability and histology were also endpoints. Results: Treated animals showed a marked reduction in small intestinal permeability. Average area under the lactulose/mannitol time curve: 5.36 (SE 0.08) in controls vs 3.97 (SE 0.07) in the high-dose AT-1001 group, p<0.05. At 8 weeks of age there was a significant reduction of colonic mucosal permeability and increased electrical resistance. By 17 weeks of age, secretion of tumour necrosis factor c (TNFα) from a colonic explant was significantly lower in the treated group (25.33 (SE 4.30( pg/mg vs 106.93 (SE 17.51) pg/ml in controls, p<0.01). All other markers also demonstrated a clear reduction of colitis in the treated animals. Additional experiments were performed which demonstrated that AT-1001 was functionally active only in the small intestine. Conclusions: This work suggests that increased intestinal permeability may be an important aetiological event in the development of colitis in IL10-/- mice.


Related Articles

  • Regulation of intestinal barrier function by signal transducer and activator of transcription 5b. Han, X.; Ren, X.; Jurickova, I.; Groschwitz, K.; Pasternak, B. A.; Xu, H.; Wilson, I. A.; Hogan, S. P.; Denson, L. A. // Gut;Jan2009, Vol. 58 Issue 1, p49 

    Background: Colon epithelial cell (CEC) apoptosis and nuclear factor-κB (NF-κB) activation may compromise barrier function, and it has been reported that signal transducer and activator of transcription 5b (STAT5b)- deficient mice exhibit increased susceptibility to colitis. It is...

  • Recent Approaches in Pathogenesis of Inflammatory Bowel Disease. Solanki, Roshni; Madat, Dhaval; Chauhan, Khushbu; Parmar, Lalkrushn // International Journal of PharmTech Research;Jul-Sep2010, Vol. 2 Issue 3, p1796 

    Inflammatory bowel disease (IBD) commonly refers to ulcerative colitis (UC) and Crohn disease (CD), which are chronic inflammatory diseases of the GI tract of unknown etiology. This inflammatory response is most likely made possible by defects in both the mucosal immune system and the barrier...

  • Maintenance of Remission in Crohn’s Disease: Current and Emerging Therapeutic Options. Brookes, Matthew J.; Green, Jonathon R.B. // Drugs;2004, Vol. 64 Issue 10, p1069 

    Crohn's disease is a chronic inflammatory bowel disorder with a relapsing and remitting course. Once remission is achieved, the main aim of the management of Crohn's disease is maintenance of that remission. Significant advances have been made into understanding the aetiology and pathogenesis of...

  • Downregulation of epithelial apoptosis and barrier repair in active Crohn's disease by tumour necrosis factor α antibody treatment. Zeissig, S.; Bojarski, C.; Buergel, N.; Monkerlz, J.; Zeitz, M.; Fromm, M.; Schulzke, J. D. // Gut;Sep2004, Vol. 53 Issue 9, p1295 

    Background and aims: Barrier dysfunction is an important feature contributing to inflammation and diarrhea in Crohn's disease (CD). Recently, tumor necrosis factor α (TNF-α) antibodies were recognised as effective in steroid refractory CD. The aim of this study was to characterize the...

  • Critical comment: analyzing the effect of novel therapies on cytokine expression in inflammatory bowel disease: do cytokine levels reflect clinical response? Wittig, B. M.; Zeitz, M. // International Journal of Colorectal Disease;Nov2006, Vol. 21 Issue 6, p505 

    Over the past several years, research in the field of cytokine production and function has become indispensable to understand the immunopathology of chronic intestinal inflammation. Thereupon, clinical studies analyzing cytokine production have generated a tremendous amount of data. In patients...

  • Adalimumab Induction Therapy for Crohn Disease Previously Treated with Infliximab. Sandborn, William J.; Rutgeerts, Paul; Enns, Robert; Hanauer, Stephen B.; Colombel, Jean-Frédéric; Panaccione, Remo; D'Haens, Geert; Li, Ju; Rosenfeld, Marie R.; Kent, Jeffrey D.; Pollack, Paul F. // Annals of Internal Medicine;6/19/2007, Vol. 146 Issue 12, p829 

    Background: Adalimumab, a fully human tumor necrosis factor (TNF) antagonist, is an effective treatment for patients with Crohn disease who are naive to the chimeric TNF antagonist, infliximab. No anti-TNF agent has been evaluated prospectively in patients with Crohn disease who had responded to...

  • The classics in perspective. Panés, Julián; Ghosh, Subrata // Gut;Sep2007, Vol. 56 Issue 9, p1184 

    The authors reflect on the development of anti-cytokine therapies as biological agents in treating Crohn's disease and inflammatory diseases. Their therapeutic approach to these diseases has expanded. They noted that gastroenterologists face a remarkable wave of new biological therapies for...

  • High serum tumor necrosis factor-α levels are associated with lack of response to infliximab in fistulizing Crohn’s disease. Martınez-Borra, Jesús; López-Larrea, Carlos; González, Segundo; Fuentes, Dolores; Dieguez, Angeles; Deschamps, Eva M.; Pérez-Pariente, J.M.; López-Vázquez, Antonio; de Francisco, Ruth; Rodrigo, Luıs // American Journal of Gastroenterology;Sep2002, Vol. 97 Issue 9, p2350 

    OBJECTIVES:Infliximab, a chimeric monoclonal antibody directed against tumor necrosis factor-α (anti-TNF-α), has been effective in the treatment of patients with active Crohn’s disease and with fistulas. We investigated the effect of infliximab on circulating cytokines and acute...

  • Anti-TNF-alpha loss of response is associated with a decreased percentage of FoxP3+ T cells and a variant NOD2 genotype in patients with Crohn's disease. Juanola, Oriol; Moratalla, Alba; Gutiérrez, Ana; Sempere, Laura; Zapater, Pedro; Giménez, Paula; Almenta, Isabel; Peiró, Gloria; González-Navajas, José; Such, José; Francés, Rubén // Journal of Gastroenterology;Jul2015, Vol. 50 Issue 7, p758 

    Background: Anti-TNF-α therapies interact with the tolerogenic response in patients with Crohn's disease, modulating inflammation. However, drug levels and the genetic background may affect this interaction. Methods: Patients with Crohn's disease in remission on biologic monotherapy were...


Read the Article


Sign out of this library

Other Topics